380 related articles for article (PubMed ID: 24516610)
1. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin.
Federici C; Petrucci F; Caimi S; Cesolini A; Logozzi M; Borghi M; D'Ilio S; Lugini L; Violante N; Azzarito T; Majorani C; Brambilla D; Fais S
PLoS One; 2014; 9(2):e88193. PubMed ID: 24516610
[TBL] [Abstract][Full Text] [Related]
2. Microenvironmental pH is a key factor for exosome traffic in tumor cells.
Parolini I; Federici C; Raggi C; Lugini L; Palleschi S; De Milito A; Coscia C; Iessi E; Logozzi M; Molinari A; Colone M; Tatti M; Sargiacomo M; Fais S
J Biol Chem; 2009 Dec; 284(49):34211-22. PubMed ID: 19801663
[TBL] [Abstract][Full Text] [Related]
3. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
[TBL] [Abstract][Full Text] [Related]
4. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.
De Milito A; Canese R; Marino ML; Borghi M; Iero M; Villa A; Venturi G; Lozupone F; Iessi E; Logozzi M; Della Mina P; Santinami M; Rodolfo M; Podo F; Rivoltini L; Fais S
Int J Cancer; 2010 Jul; 127(1):207-19. PubMed ID: 19876915
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
Hekmatirad S; Moloudizargari M; Moghadamnia AA; Kazemi S; Mohammadnia-Afrouzi M; Baeeri M; Moradkhani F; Asghari MH
Front Immunol; 2021; 12():692654. PubMed ID: 34149737
[TBL] [Abstract][Full Text] [Related]
6. Acidic microenvironment plays a key role in human melanoma progression through a sustained exosome mediated transfer of clinically relevant metastatic molecules.
Boussadia Z; Lamberti J; Mattei F; Pizzi E; Puglisi R; Zanetti C; Pasquini L; Fratini F; Fantozzi L; Felicetti F; Fecchi K; Raggi C; Sanchez M; D'Atri S; Carè A; Sargiacomo M; Parolini I
J Exp Clin Cancer Res; 2018 Oct; 37(1):245. PubMed ID: 30290833
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors may reduce tumour resistance.
De Milito A; Fais S
Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
[TBL] [Abstract][Full Text] [Related]
8. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma.
Azzarito T; Venturi G; Cesolini A; Fais S
Cancer Lett; 2015 Jan; 356(2 Pt B):697-703. PubMed ID: 25449440
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistant P-glycoprotein positive L1210/VCR cells are also cross-resistant to cisplatin via a mechanism distinct from P-glycoprotein-mediated drug efflux activity.
Gibalová L; Sedlák J; Labudová M; Barancík M; Reháková A; Breier A; Sulová Z
Gen Physiol Biophys; 2009 Dec; 28(4):391-403. PubMed ID: 20097962
[TBL] [Abstract][Full Text] [Related]
10. Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures.
Galé A; Hofmann L; Lüdi N; Hungerbühler MN; Kempf C; Heverhagen JT; von Tengg-Kobligk H; Broekmann P; Ruprecht N
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502377
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.
Fais S
J Intern Med; 2010 May; 267(5):515-25. PubMed ID: 20433578
[TBL] [Abstract][Full Text] [Related]
12. Tumor acidity, chemoresistance and proton pump inhibitors.
De Milito A; Fais S
Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
[TBL] [Abstract][Full Text] [Related]
13. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance.
Song W; Tang Z; Shen N; Yu H; Jia Y; Zhang D; Jiang J; He C; Tian H; Chen X
J Control Release; 2016 Jun; 231():94-102. PubMed ID: 26928530
[TBL] [Abstract][Full Text] [Related]
14. Interaction between the anticancer drug Cisplatin and the copper chaperone Atox1 in human melanoma cells.
Palm-Espling ME; Lundin C; Björn E; Naredi P; Wittung-Stafshede P
Protein Pept Lett; 2014; 21(1):63-8. PubMed ID: 23988033
[TBL] [Abstract][Full Text] [Related]
15. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells.
Chen M; Zou X; Luo H; Cao J; Zhang X; Zhang B; Liu W
Cell Biol Int; 2009 Sep; 33(9):1008-19. PubMed ID: 19501661
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.
Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z
Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
18.
Vermathen M; von Tengg-Kobligk H; Hungerbühler MN; Vermathen P; Ruprecht N
Molecules; 2021 Nov; 26(22):. PubMed ID: 34833859
[TBL] [Abstract][Full Text] [Related]
19. Tobacco Mosaic Virus-Delivered Cisplatin Restores Efficacy in Platinum-Resistant Ovarian Cancer Cells.
Franke CE; Czapar AE; Patel RB; Steinmetz NF
Mol Pharm; 2018 Aug; 15(8):2922-2931. PubMed ID: 28926265
[TBL] [Abstract][Full Text] [Related]
20. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
